Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overview of Subcutaneous Metastatic Melanoma.

Literature DB >> 33922905

Overview of Subcutaneous Metastatic Melanoma.

Nicola Mozzillo¹.

Abstract

Melanoma is among the most common primary solid tumors with cutaneous and subcutaneous metastasis [...].

Entities: Chemical Disease Gene Species

Year: 2021 PMID： 33922905 DOI： 10.3390/cancers13092063

Source DB: PubMed Journal: Cancers (Basel) ISSN： 2072-6694 Impact factor: 6.639

12 in total

1. Predicting outcomes in metastatic melanoma.

Authors: Charles M Balch; Seng-Jaw Soong
Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544

2. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245

3. Fine needle aspiration in the diagnosis of metastatic melanoma.

Authors: L K Rodrigues; S P Leong; B M Ljung; R W Sagebiel; N Burnside; T l Hu; B W Ng; J R Miller; M Kashani-Sabet
Journal: J Am Acad Dermatol Date: 2000-05 Impact factor: 11.527

4. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Authors: Rodabe N Amaria; Peter A Prieto; Michael T Tetzlaff; Alexandre Reuben; Miles C Andrews; Merrick I Ross; Isabella C Glitza; Janice Cormier; Wen-Jen Hwu; Hussein A Tawbi; Sapna P Patel; Jeffrey E Lee; Jeffrey E Gershenwald; Christine N Spencer; Vancheswaran Gopalakrishnan; Roland Bassett; Lauren Simpson; Rosalind Mouton; Courtney W Hudgens; Li Zhao; Haifeng Zhu; Zachary A Cooper; Khalida Wani; Alexander Lazar; Patrick Hwu; Adi Diab; Michael K Wong; Jennifer L McQuade; Richard Royal; Anthony Lucci; Elizabeth M Burton; Sangeetha Reddy; Padmanee Sharma; James Allison; Phillip A Futreal; Scott E Woodman; Michael A Davies; Jennifer A Wargo
Journal: Lancet Oncol Date: 2018-01-18 Impact factor: 41.316

5. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Authors: Paolo A Ascierto; Georgina V Long; Caroline Robert; Benjamin Brady; Caroline Dutriaux; Anna Maria Di Giacomo; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Lars Ny; Ana Arance; Inge Marie Svane; Dirk Schadendorf; Helen Gogas; Abdel Saci; Joel Jiang; Jasmine Rizzo; Victoria Atkinson
Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777

6. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors: Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316

7. Contemporary surgical treatment of advanced-stage melanoma.

Authors: Richard Essner; Jonathan H Lee; Leslie A Wanek; Hitoe Itakura; Donald L Morton
Journal: Arch Surg Date: 2004-09

8. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Authors: Mark B Faries; Nicola Mozzillo; Mohammed Kashani-Sabet; John F Thompson; Mark C Kelley; Ronald C DeConti; Jeffrey E Lee; James F Huth; Jeffrey Wagner; Angus Dalgleish; Daniel Pertschuk; Christopher Nardo; Stacey Stern; Robert Elashoff; Guy Gammon; Donald L Morton
Journal: Ann Surg Oncol Date: 2017-10-10 Impact factor: 5.344

9. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma.

Authors: Nicola Mozzillo; Corrado Caracò; Stefano Mori; Gianluca Di Monta; Gerardo Botti; Paolo A Ascierto; Corradina Caracò; Luigi Aloj
Journal: J Transl Med Date: 2012-06-22 Impact factor: 5.531

10. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Authors: Gang Chen; Alexander C Huang; Wei Zhang; Gao Zhang; Min Wu; Wei Xu; Zili Yu; Jiegang Yang; Beike Wang; Honghong Sun; Houfu Xia; Qiwen Man; Wenqun Zhong; Leonardo F Antelo; Bin Wu; Xuepeng Xiong; Xiaoming Liu; Lei Guan; Ting Li; Shujing Liu; Ruifeng Yang; Youtao Lu; Liyun Dong; Suzanne McGettigan; Rajasekharan Somasundaram; Ravi Radhakrishnan; Gordon Mills; Yiling Lu; Junhyong Kim; Youhai H Chen; Haidong Dong; Yifang Zhao; Giorgos C Karakousis; Tara C Mitchell; Lynn M Schuchter; Meenhard Herlyn; E John Wherry; Xiaowei Xu; Wei Guo
Journal: Nature Date: 2018-08-08 Impact factor: 49.962